Corvus Pharmaceuticals, Inc. Basic Shares Outstanding (Weighted Average)
Corvus Pharmaceuticals, Inc. (CRVS) reported Basic Shares Outstanding (Weighted Average) of 92.37 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 92.37M shares, a 18.76% increase year-over-year.
- Corvus Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 90.00M shares, a 24.78% increase year-over-year.
- Corvus Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 83.00M shares, a 21.35% increase year-over-year.
- Corvus Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 82.84M shares, a 24.19% increase year-over-year.
- Corvus Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 78.96M shares, a 29.48% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 60.99M shares, a 26.99% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 48.03M shares, a 3.16% increase from fiscal 2022.
- Corvus Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 46.55M shares, a 11.23% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 92.37M shares 10-Q · filed 2026-08-06 | 91.19M shares 10-Q · filed 2026-08-06 | 88.46M shares derived: average of 3 quarters · filed 2026-08-06 | 87.05M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 90.00M shares 10-Q · filed 2026-05-07 | 86.50M shares derived: average of 2 quarters · filed 2026-05-07 | 85.28M shares derived: average of 3 quarters · filed 2026-05-07 | 83.40M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 83.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 82.92M shares derived: average of 2 quarters · filed 2026-03-12 | 81.21M shares derived: average of 3 quarters · filed 2026-08-06 | 78.96M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 82.84M shares 10-Q · filed 2025-11-04 | 80.31M shares derived: average of 2 quarters · filed 2026-08-06 | 77.62M shares 10-Q · filed 2025-11-04 | 75.28M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 77.77M shares 10-Q · filed 2026-08-06 | 74.97M shares 10-Q · filed 2026-08-06 | 72.77M shares derived: average of 3 quarters · filed 2026-08-06 | 71.25M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 72.13M shares 10-Q · filed 2026-05-07 | 70.26M shares derived: average of 2 quarters · filed 2026-05-07 | 69.08M shares derived: average of 3 quarters · filed 2026-05-07 | 66.73M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 68.40M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 67.55M shares derived: average of 2 quarters · filed 2026-03-12 | 64.94M shares derived: average of 3 quarters · filed 2026-03-12 | 60.99M shares 10-K · filed 2026-03-12 |
| 2024-09-30 | 66.70M shares 10-Q · filed 2025-11-04 | 63.21M shares derived: average of 2 quarters · filed 2025-11-04 | 58.51M shares 10-Q · filed 2025-11-04 | 56.12M shares derived: average of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | 59.71M shares 10-Q · filed 2025-08-07 | 54.37M shares 10-Q · filed 2025-08-07 | 52.60M shares derived: average of 3 quarters · filed 2026-03-12 | 51.69M shares derived: average of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | 49.04M shares 10-Q · filed 2025-05-08 | 49.04M shares derived: average of 2 quarters · filed 2026-03-12 | 49.02M shares derived: average of 3 quarters · filed 2026-03-12 | 48.64M shares derived: average of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | 49.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 49.01M shares derived: average of 2 quarters · filed 2026-03-12 | 48.51M shares derived: average of 3 quarters · filed 2026-03-12 | 48.03M shares 10-K · filed 2026-03-12 |
| 2023-09-30 | 48.97M shares 10-Q · filed 2024-11-12 | 48.23M shares derived: average of 2 quarters · filed 2024-11-12 | 47.68M shares 10-Q · filed 2024-11-12 | 47.39M shares derived: average of 4 quarters · filed 2025-03-25 |
| 2023-06-30 | 47.50M shares 10-Q · filed 2024-08-06 | 47.03M shares 10-Q · filed 2024-08-06 | 46.87M shares derived: average of 3 quarters · filed 2025-03-25 | 46.79M shares derived: average of 4 quarters · filed 2025-03-25 |
| 2023-03-31 | 46.56M shares 10-Q · filed 2024-05-07 | 46.55M shares derived: average of 2 quarters · filed 2025-03-25 | 46.55M shares derived: average of 3 quarters · filed 2025-03-25 | 46.55M shares derived: average of 4 quarters · filed 2025-03-25 |
| 2022-12-31 | 46.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | 46.55M shares derived: average of 2 quarters · filed 2025-03-25 | 46.55M shares derived: average of 3 quarters · filed 2025-03-25 | 46.55M shares 10-K · filed 2025-03-25 |
| 2022-09-30 | 46.55M shares 10-Q · filed 2023-11-07 | 46.55M shares derived: average of 2 quarters · filed 2023-11-07 | 46.55M shares 10-Q · filed 2023-11-07 | 46.57M shares derived: average of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | 46.55M shares 10-Q · filed 2023-08-08 | 46.55M shares 10-Q · filed 2023-08-08 | 46.57M shares derived: average of 3 quarters · filed 2024-03-19 | 45.91M shares derived: average of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | 46.55M shares 10-Q · filed 2023-05-08 | 46.58M shares derived: average of 2 quarters · filed 2024-03-19 | 45.70M shares derived: average of 3 quarters · filed 2024-03-19 | 44.84M shares derived: average of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | 46.60M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 45.28M shares derived: average of 2 quarters · filed 2024-03-19 | 44.27M shares derived: average of 3 quarters · filed 2024-03-19 | 41.85M shares 10-K · filed 2024-03-19 |
| 2021-09-30 | 43.95M shares 10-Q · filed 2022-11-03 | 43.10M shares derived: average of 2 quarters · filed 2022-11-03 | 40.27M shares 10-Q · filed 2022-11-03 | |
| 2021-06-30 | 42.25M shares 10-Q · filed 2022-08-08 | 38.40M shares 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | 34.52M shares 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 29.48M shares 10-K · filed 2023-03-28 | |||
| 2019-12-31 | 29.35M shares 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |